CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma

The application of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer has significantly improved patient survival. However, most patients fail to respond to ICIs or develop drug resistance during treatment. Therefore, novel biomarkers are needed to predict the efficacy of ICIs or prov...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wengang, Shang, Xiaoling, Yang, Fei, Han, Wenfei, Xia, Handai, Liu, Ni, Liu, Yanguo, Wang, Xiuwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104567/
https://www.ncbi.nlm.nih.gov/pubmed/35574406
http://dx.doi.org/10.3389/fonc.2022.867788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104567/
https://www.ncbi.nlm.nih.gov/pubmed/35574406
http://dx.doi.org/10.3389/fonc.2022.867788

Ejemplares similares